“COVID-19’s existence anywhere poses a threat to communities everywhere,” the statement said.
The drugmakers that signed the statement are: AstraZeneca, Bayer, bioMérieux, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Merck KGaA, Novartis, Pfizer, Roche and Sanofi.
The companies said they have launched the most “expansive and ambitious” pandemic research and development response in history and promised a range of interventions to help end the pandemic.
The pledge includes promises to:
- Develop innovations for patients worldwide
- Strive for timely availability of diagnostics, therapies and vaccines
- Enable affordability for lower income countries
- Support effective and equitable distribution of these innovations globally
- Maintain public confidence in their innovations
The joint statement also calls on government, multilateral institutions, companies, nongovernmental organizations and others to:
- Provide sufficient, dedicated, sustainable, timely funding
- Diversify representation in decision-making committees
- Continue quickly developing and communicating clear guidance
- Advance fit-for-purpose regulatory and liability processes for all stakeholders
- Build and maintain public confidence
- Enhance country readiness and in-country delivery systems
“The world’s extraordinary situation requires unprecedented collaboration across every part of society,” the companies wrote.
Read the full statement here.
More articles on pharmacy:
FDA expands probe of AstraZeneca’s COVID-19 vaccine; US trial still delayed
Government stops distributing remdesivir
Oxford University to test AbbVie’s Humira as COVID-19 treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.